Quick Take
Trevi Therapeutics (TRVI) intends to raise $70.0 million from the sale of common stock in an IPO, per an amended registration statement.
The company is advancing a series of treatment programs for various conditions that may be treated by its nalbuphine ER compound.
TRVI has achieved promising Phase 2 trial results and expects topline data from its Phase 3 trials in 1H 2020.
Company & Technology
New Haven, Connecticut-based Trevi was founded in 2011 to develop nalbuphine ER for the treatment of conditions sharing common pathophysiology that is mediated through